Lung Cancer Screening in Asymptomatic Pts | USPSTF, ACCP, ACS, AATS, etc Guideline Synthesis Submitted by switaschek on Thu, 10/15/2020 - 23:17 Read more about Lung Cancer Screening in Asymptomatic Pts | USPSTF, ACCP, ACS, AATS, etc Guideline Synthesis
Booster dose 1 dose 2mo after primary series may give heterologous booster doses but eligibility and dosing interval should follow primary series product Submitted by vgreene on Mon, 10/25/2021 - 17:01 Read more about Booster dose 1 dose 2mo after primary series may give heterologous booster doses but eligibility and dosing interval should follow primary series product
Strong antibody response in children 5 11 yo similar to young adults per phase 2 3 study press release Submitted by vgreene on Mon, 10/25/2021 - 16:58 Read more about Strong antibody response in children 5 11 yo similar to young adults per phase 2 3 study press release
Booster dose 1 dose 0 25 mL 6mo after primary series in pts 65 yo or 18 64 yo at high risk for severe COVID 19 or frequent institutional or occupational exposure may give heterologous booster doses but eligibility and dosing interval should follow primary Submitted by vgreene on Mon, 10/25/2021 - 16:51 Read more about Booster dose 1 dose 0 25 mL 6mo after primary series in pts 65 yo or 18 64 yo at high risk for severe COVID 19 or frequent institutional or occupational exposure may give heterologous booster doses but eligibility and dosing interval should follow primary
Booster dose 95 6 relative vaccine efficacy compared w no booster dose per preliminary analysis Submitted by vgreene on Mon, 10/25/2021 - 16:46 Read more about Booster dose 95 6 relative vaccine efficacy compared w no booster dose per preliminary analysis
Strong antibody response in children 5 11 yo similar to 16 25 yo per preliminary analysis Submitted by vgreene on Mon, 10/25/2021 - 16:45 Read more about Strong antibody response in children 5 11 yo similar to 16 25 yo per preliminary analysis
Quick Sx Comparison: COVID-19 vs Flu vs Cold:<sup>1</sup> Submitted by vgreene on Thu, 10/21/2021 - 19:33 Read more about Quick Sx Comparison: COVID-19 vs Flu vs Cold:1
Phase 3 ACTT 3 Trial Reveals No Greater Benefit With Interferon Beta 1a Plus Remdesivir Versus Remdesivir Alone In Hospitalized Patients With COVID 19 Pneumonia access Lancet Respir Med article Submitted by vgreene on Thu, 10/21/2021 - 18:19 Read more about Phase 3 ACTT 3 Trial Reveals No Greater Benefit With Interferon Beta 1a Plus Remdesivir Versus Remdesivir Alone In Hospitalized Patients With COVID 19 Pneumonia access Lancet Respir Med article
93 effective against hospitalization in 12 18 yo per CDC Submitted by vgreene on Thu, 10/21/2021 - 18:16 Read more about 93 effective against hospitalization in 12 18 yo per CDC
<b>Quick Sx Comparison: COVID-19 vs Flu vs Cold</b><sup>1</sup> Submitted by vgreene on Thu, 10/21/2021 - 16:46 Read more about Quick Sx Comparison: COVID-19 vs Flu vs Cold1
